Analyst Price Target is $42.33
▲ +11.26% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Tyra Biosciences in the last 3 months. The average price target is $42.33, with a high forecast of $53.00 and a low forecast of $35.00. The average price target represents a 11.26% upside from the last price of $38.05.
Current Consensus is
Moderate Buy
The current consensus among 10 investment analysts is to moderate buy stock in Tyra Biosciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Read More
